JP7340127B2 - がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体 - Google Patents
がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体 Download PDFInfo
- Publication number
- JP7340127B2 JP7340127B2 JP2018548022A JP2018548022A JP7340127B2 JP 7340127 B2 JP7340127 B2 JP 7340127B2 JP 2018548022 A JP2018548022 A JP 2018548022A JP 2018548022 A JP2018548022 A JP 2018548022A JP 7340127 B2 JP7340127 B2 JP 7340127B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- tcr
- cells
- sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091008874 T cell receptors Proteins 0.000 title claims description 513
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims description 513
- 206010028980 Neoplasm Diseases 0.000 title claims description 108
- 210000001744 T-lymphocyte Anatomy 0.000 title description 118
- 201000011510 cancer Diseases 0.000 title description 56
- 238000009169 immunotherapy Methods 0.000 title description 9
- 210000004027 cell Anatomy 0.000 claims description 275
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 252
- 238000000034 method Methods 0.000 claims description 110
- 150000001413 amino acids Chemical class 0.000 claims description 78
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 73
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 69
- 239000000427 antigen Substances 0.000 claims description 66
- 150000007523 nucleic acids Chemical class 0.000 claims description 66
- 108091007433 antigens Proteins 0.000 claims description 64
- 102000036639 antigens Human genes 0.000 claims description 64
- 102000039446 nucleic acids Human genes 0.000 claims description 61
- 108020004707 nucleic acids Proteins 0.000 claims description 61
- 241000282414 Homo sapiens Species 0.000 claims description 55
- 239000013598 vector Substances 0.000 claims description 52
- 238000006467 substitution reaction Methods 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 20
- 230000028993 immune response Effects 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 208000032839 leukemia Diseases 0.000 claims description 11
- 241001529936 Murinae Species 0.000 claims description 9
- 108010050904 Interferons Proteins 0.000 claims description 8
- 102000014150 Interferons Human genes 0.000 claims description 8
- 229940079322 interferon Drugs 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 7
- 108091026890 Coding region Proteins 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000004873 anchoring Methods 0.000 claims 1
- 230000009258 tissue cross reactivity Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 135
- 235000001014 amino acid Nutrition 0.000 description 90
- 229940024606 amino acid Drugs 0.000 description 76
- 229920001184 polypeptide Polymers 0.000 description 62
- 230000014509 gene expression Effects 0.000 description 55
- 108090000623 proteins and genes Proteins 0.000 description 55
- 230000027455 binding Effects 0.000 description 54
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 52
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 52
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 48
- 108020004414 DNA Proteins 0.000 description 38
- 239000013604 expression vector Substances 0.000 description 36
- 102000011786 HLA-A Antigens Human genes 0.000 description 33
- 108010075704 HLA-A Antigens Proteins 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 31
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 29
- 239000012634 fragment Substances 0.000 description 28
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 26
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 26
- 230000000875 corresponding effect Effects 0.000 description 24
- 210000004881 tumor cell Anatomy 0.000 description 22
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 20
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 20
- 101001005720 Homo sapiens Melanoma-associated antigen 4 Proteins 0.000 description 18
- 102100025077 Melanoma-associated antigen 4 Human genes 0.000 description 18
- 108010004729 Phycoerythrin Proteins 0.000 description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 description 17
- 238000000338 in vitro Methods 0.000 description 17
- 102000040430 polynucleotide Human genes 0.000 description 17
- 108091033319 polynucleotide Proteins 0.000 description 17
- 239000002157 polynucleotide Substances 0.000 description 17
- 239000012636 effector Substances 0.000 description 16
- 108091023037 Aptamer Proteins 0.000 description 15
- 125000000539 amino acid group Chemical group 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 230000035772 mutation Effects 0.000 description 15
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 14
- 108091054437 MHC class I family Proteins 0.000 description 13
- 206010033128 Ovarian cancer Diseases 0.000 description 13
- 206010061535 Ovarian neoplasm Diseases 0.000 description 13
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 206010006187 Breast cancer Diseases 0.000 description 12
- 208000026310 Breast neoplasm Diseases 0.000 description 12
- 206010041067 Small cell lung cancer Diseases 0.000 description 12
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 12
- 208000000587 small cell lung carcinoma Diseases 0.000 description 12
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 11
- 108010074328 Interferon-gamma Proteins 0.000 description 11
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 11
- 102000015636 Oligopeptides Human genes 0.000 description 11
- 108010038807 Oligopeptides Proteins 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 11
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 201000004101 esophageal cancer Diseases 0.000 description 11
- 201000001441 melanoma Diseases 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 206010005003 Bladder cancer Diseases 0.000 description 10
- 208000003174 Brain Neoplasms Diseases 0.000 description 10
- 206010009944 Colon cancer Diseases 0.000 description 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 10
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 10
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 10
- 206010060862 Prostate cancer Diseases 0.000 description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 description 10
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 10
- 208000002495 Uterine Neoplasms Diseases 0.000 description 10
- 210000000612 antigen-presenting cell Anatomy 0.000 description 10
- 208000006990 cholangiocarcinoma Diseases 0.000 description 10
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 108020001507 fusion proteins Proteins 0.000 description 10
- 102000037865 fusion proteins Human genes 0.000 description 10
- 210000000232 gallbladder Anatomy 0.000 description 10
- 201000010175 gallbladder cancer Diseases 0.000 description 10
- 206010017758 gastric cancer Diseases 0.000 description 10
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 230000002147 killing effect Effects 0.000 description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 10
- 201000002528 pancreatic cancer Diseases 0.000 description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 description 10
- 201000011549 stomach cancer Diseases 0.000 description 10
- 201000005112 urinary bladder cancer Diseases 0.000 description 10
- 206010046766 uterine cancer Diseases 0.000 description 10
- 206010004593 Bile duct cancer Diseases 0.000 description 9
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 9
- 102000043129 MHC class I family Human genes 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 208000026900 bile duct neoplasm Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- -1 oligopeptides Chemical class 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 8
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 7
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 7
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 7
- 241000713666 Lentivirus Species 0.000 description 7
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 7
- 230000006044 T cell activation Effects 0.000 description 7
- 230000000735 allogeneic effect Effects 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 238000003501 co-culture Methods 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 239000003053 toxin Substances 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 108700012359 toxins Proteins 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 6
- 101000662909 Homo sapiens T cell receptor beta constant 1 Proteins 0.000 description 6
- 101000662902 Homo sapiens T cell receptor beta constant 2 Proteins 0.000 description 6
- 108091054438 MHC class II family Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 102100037272 T cell receptor beta constant 1 Human genes 0.000 description 6
- 102100037298 T cell receptor beta constant 2 Human genes 0.000 description 6
- 230000005867 T cell response Effects 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 230000001131 transforming effect Effects 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000006354 HLA-DR Antigens Human genes 0.000 description 5
- 108010058597 HLA-DR Antigens Proteins 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000001902 propagating effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000005304 joining Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- 102000000704 Interleukin-7 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 108700042076 T-Cell Receptor alpha Genes Proteins 0.000 description 3
- 108700042077 T-Cell Receptor beta Genes Proteins 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 102200082402 rs751610198 Human genes 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 2
- 108010058607 HLA-B Antigens Proteins 0.000 description 2
- 108010052199 HLA-C Antigens Proteins 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000798076 Homo sapiens T cell receptor delta constant Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 2
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 102100032272 T cell receptor delta constant Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 238000012867 alanine scanning Methods 0.000 description 2
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000741 isoleucyl group Chemical class [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 108010011903 peptide receptors Proteins 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 102100035682 Axin-1 Human genes 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 1
- 238000012492 Biacore method Methods 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 206010062759 Congenital dyskeratosis Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 108091008102 DNA aptamers Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 108010021727 HLA-A*24:02 antigen Proteins 0.000 description 1
- 108010008553 HLA-B*07 antigen Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000874566 Homo sapiens Axin-1 Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000624960 Homo sapiens Nesprin-3 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 102100026964 M1-specific T cell receptor beta chain Human genes 0.000 description 1
- 101150010540 MAGEA4 gene Proteins 0.000 description 1
- 101100096028 Mus musculus Smok1 gene Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102100023307 Nesprin-3 Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000012163 TRI reagent Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000009356 dyskeratosis congenita Diseases 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940100994 interleukin-7 Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000003794 male germ cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000007347 radical substitution reaction Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000004621 scanning probe microscopy Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4269—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023039404A JP7559120B2 (ja) | 2016-03-16 | 2023-03-14 | がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体 |
| JP2024160597A JP2025011091A (ja) | 2016-03-16 | 2024-09-18 | がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308975P | 2016-03-16 | 2016-03-16 | |
| GBGB1604492.7A GB201604492D0 (en) | 2016-03-16 | 2016-03-16 | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| US62/308,975 | 2016-03-16 | ||
| GB1604492.7 | 2016-03-16 | ||
| PCT/EP2017/056260 WO2017158103A1 (en) | 2016-03-16 | 2017-03-16 | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023039404A Division JP7559120B2 (ja) | 2016-03-16 | 2023-03-14 | がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511222A JP2019511222A (ja) | 2019-04-25 |
| JP2019511222A5 JP2019511222A5 (enExample) | 2020-04-16 |
| JP7340127B2 true JP7340127B2 (ja) | 2023-09-07 |
Family
ID=55952417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548022A Active JP7340127B2 (ja) | 2016-03-16 | 2017-03-16 | がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10538573B2 (enExample) |
| EP (1) | EP3430030B1 (enExample) |
| JP (1) | JP7340127B2 (enExample) |
| KR (2) | KR102457504B1 (enExample) |
| CN (1) | CN108884136B (enExample) |
| AU (2) | AU2017235467B2 (enExample) |
| CA (1) | CA3017502A1 (enExample) |
| CR (1) | CR20180492A (enExample) |
| EA (1) | EA201892021A1 (enExample) |
| GB (1) | GB201604492D0 (enExample) |
| MA (2) | MA43720A (enExample) |
| MX (1) | MX2018011225A (enExample) |
| MY (1) | MY189042A (enExample) |
| SG (1) | SG11201807868VA (enExample) |
| TW (1) | TWI764886B (enExample) |
| WO (1) | WO2017158103A1 (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI707038B (zh) | 2013-08-05 | 2020-10-11 | 美商扭轉生物科技有限公司 | 重新合成之基因庫 |
| WO2016126882A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| KR20180050411A (ko) | 2015-09-18 | 2018-05-14 | 트위스트 바이오사이언스 코포레이션 | 올리고핵산 변이체 라이브러리 및 그의 합성 |
| CN108698012A (zh) | 2015-09-22 | 2018-10-23 | 特韦斯特生物科学公司 | 用于核酸合成的柔性基底 |
| WO2017095958A1 (en) | 2015-12-01 | 2017-06-08 | Twist Bioscience Corporation | Functionalized surfaces and preparation thereof |
| DK3430030T5 (da) | 2016-03-16 | 2024-09-23 | Immatics Biotechnologies Gmbh | Transficerede t-celler og t-cellereceptorer til anvendelse i immunoterapi mod cancer |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| KR102212257B1 (ko) | 2016-08-22 | 2021-02-04 | 트위스트 바이오사이언스 코포레이션 | 드 노보 합성된 핵산 라이브러리 |
| WO2018057526A2 (en) | 2016-09-21 | 2018-03-29 | Twist Bioscience Corporation | Nucleic acid based data storage |
| RS62865B1 (sr) | 2016-12-08 | 2022-02-28 | Immatics Biotechnologies Gmbh | Novi t-ćelijski receptori i imunoterapija u kojoj se koriste |
| DE102016123847B3 (de) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| EP3554514A4 (en) | 2016-12-16 | 2020-08-05 | Twist Bioscience Corporation | BANKS OF VARIANTS OF IMMUNOLOGICAL SYNAPSE AND THEIR SYNTHESIS |
| CN110892485B (zh) | 2017-02-22 | 2024-03-22 | 特韦斯特生物科学公司 | 基于核酸的数据存储 |
| AU2018234629A1 (en) | 2017-03-15 | 2019-10-17 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
| EP3609530A1 (en) * | 2017-04-10 | 2020-02-19 | Immatics Biotechnologies GmbH | Peptides and combination thereof for use in the immunotherapy against cancers |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| JP7169999B2 (ja) | 2017-06-12 | 2022-11-11 | ツイスト バイオサイエンス コーポレーション | シームレス核酸アセンブリのための方法 |
| AU2018328847A1 (en) | 2017-09-11 | 2020-04-23 | Twist Bioscience Corporation | GPCR binding proteins and synthesis thereof |
| US11598780B2 (en) * | 2017-10-06 | 2023-03-07 | The University Of Chicago | Engineering lymphocytes with specific alpha and beta chains on their t-cell receptor |
| CA3081336A1 (en) | 2017-10-12 | 2019-04-18 | Gregory LIZEE | T cell receptors for immunotherapy |
| WO2019079769A1 (en) | 2017-10-20 | 2019-04-25 | Twist Bioscience Corporation | HEATED NANOWELLS FOR THE SYNTHESIS OF POLYNUCLEOTIDES |
| EP4715681A2 (en) | 2018-01-04 | 2026-03-25 | Atlas Data Storage, Inc. | Dna-based digital information storage |
| GB201803750D0 (en) | 2018-03-08 | 2018-04-25 | Immunocore Ltd | Method |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| WO2019196088A1 (en) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
| IL278771B2 (en) | 2018-05-18 | 2025-09-01 | Twist Bioscience Corp | Polynucleotides, reagents and methods for nucleic acid hybridization |
| JP7558151B2 (ja) * | 2018-09-05 | 2024-09-30 | アダプティミューン・リミテッド | Ｔ細胞改変 |
| MA53599A (fr) * | 2018-09-14 | 2021-07-21 | Immatics Biotechnologies Gmbh | Procédé de criblage par affinité peptide-cmh à haut débit destiné à des ligands de tcr |
| DE102018122546B3 (de) | 2018-09-14 | 2019-12-05 | Immatics Biotechnologies Gmbh | Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden |
| CN112912391A (zh) * | 2018-10-25 | 2021-06-04 | 昆士兰医学研究所理事会 | T细胞受体及其用途 |
| GB201819540D0 (en) | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| WO2020139871A1 (en) | 2018-12-26 | 2020-07-02 | Twist Bioscience Corporation | Highly accurate de novo polynucleotide synthesis |
| AU2020227802A1 (en) | 2019-02-26 | 2021-10-14 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
| WO2020176678A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for glp1 receptor |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| CN111748028A (zh) * | 2019-03-29 | 2020-10-09 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
| CN111748029B (zh) * | 2019-03-29 | 2022-12-13 | 苏州蓝马医疗技术有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
| MX2021013588A (es) * | 2019-05-08 | 2022-02-11 | Medigene Immunotherapies Gmbh | Células t genomodificadas. |
| MA56036A (fr) | 2019-05-27 | 2022-04-06 | Immatics Us Inc | Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive |
| CN118994364A (zh) * | 2019-06-18 | 2024-11-22 | 里珍纳龙药品有限公司 | Mage-a4 t细胞受体及其使用方法 |
| EP3986450A4 (en) * | 2019-06-20 | 2023-06-28 | Memorial Sloan Kettering Cancer Center | T cell receptors targeting pik3ca mutations and uses thereof |
| CA3144644A1 (en) | 2019-06-21 | 2020-12-24 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| CN110357953B (zh) * | 2019-07-17 | 2022-05-03 | 深圳市因诺转化医学研究院 | 识别人巨细胞病毒pp65抗原的TCR |
| WO2021019474A1 (en) * | 2019-07-30 | 2021-02-04 | University Health Network | Mhc class ii molecules and methods of use thereof |
| DE102019121007A1 (de) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| US12091777B2 (en) | 2019-09-23 | 2024-09-17 | Twist Bioscience Corporation | Variant nucleic acid libraries for CRTH2 |
| EP4034564A4 (en) | 2019-09-23 | 2023-12-13 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID LIBRARIES FOR SINGLE-DOMAIN ANTIBODIES |
| BR112022011235A2 (pt) | 2019-12-09 | 2022-12-13 | Twist Bioscience Corp | Bibliotecas de variantes de ácido nucleico para receptores de adenosina |
| AU2021206644A1 (en) * | 2020-01-06 | 2022-07-28 | Memorial Hospital For Cancer And Allied Diseases | Novel dominant negative Fas polypeptides, cells comprising thereof and uses thereof |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| CN113621070A (zh) * | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| US20220056411A1 (en) * | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| JP7644421B2 (ja) * | 2020-10-07 | 2025-03-12 | ダアン バイオセラピュティクス カンパニー、リミテッド | Ｔ細胞受容体、ｔ細胞受容体を含む免疫細胞およびそれを用いる方法｛ｔ ｃｅｌｌ ｒｅｃｅｐｔｏｒｓ、ｉｍｍｕｎｅ ｃｅｌｌ ｃｏｍｐｒｉｓｉｎｇ ｔ ｃｅｌｌ ｒｅｃｅｐｔｏｒｓ ａｎｄ ｍｅｔｈｏｄ ｕｓｉｎｇ ｔｈｅ ｓａｍｅ｝ |
| PE20250846A1 (es) | 2020-12-31 | 2025-03-21 | Immatics Us Inc | Polipeptidos cd8, composiciones y metodos de uso de estos |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| CN115975003B (zh) * | 2021-03-09 | 2024-01-26 | 科士华(南京)生物技术有限公司 | Tcr、多肽、表达载体、宿主细胞、药物组合物和tcr获得方法 |
| KR20230159851A (ko) * | 2021-03-22 | 2023-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 결정하는 방법 |
| WO2022225836A1 (en) * | 2021-04-21 | 2022-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i-restricted t cell receptors against ras with q61k mutation |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| CN113337514B (zh) * | 2021-08-05 | 2021-10-29 | 卡瑞济(北京)生命科技有限公司 | Tcr表达构建体以及其制备方法和用途 |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| CN113773378B (zh) * | 2021-10-14 | 2023-11-03 | 深圳大学总医院 | T细胞受体及其应用 |
| EP4414388A4 (en) * | 2021-11-03 | 2025-10-29 | Curon Biopharmaceutical Shanghai Co Ltd | NEW ANTI-L1CAM ANTIBODY |
| WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| US20250134999A1 (en) | 2022-01-14 | 2025-05-01 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
| CA3247927A1 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression |
| EP4472742A1 (en) * | 2022-02-03 | 2024-12-11 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| WO2023183758A2 (en) * | 2022-03-19 | 2023-09-28 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules targeting cd3 and mage-a4 and uses thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| IL316515A (en) | 2022-04-28 | 2024-12-01 | Immatics Us Inc | Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| EP4543911A2 (en) * | 2022-06-24 | 2025-04-30 | Amgen Inc. | Magea4 specific t cell receptors |
| US20260055158A1 (en) * | 2022-08-08 | 2026-02-26 | The University Of North Carolina At Chapel Hill | Bioorthogonal t cell receptor molecules and methods of making and using the same |
| WO2024064642A2 (en) | 2022-09-19 | 2024-03-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for modulating t cell function |
| WO2025029835A1 (en) | 2023-07-31 | 2025-02-06 | Tune Therapeutics, Inc. | Compositions and methods for modulating il-2 gene expression |
| WO2025029840A1 (en) | 2023-07-31 | 2025-02-06 | Tune Therapeutics, Inc. | Compositions and methods for multiplexed activation and repression of t cell gene expression |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025233432A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide |
| WO2026008886A1 (en) | 2024-07-05 | 2026-01-08 | Immatics Biotechnologies Gmbh | Means and methods for the quantification of target expression |
| WO2026082746A1 (en) | 2024-10-14 | 2026-04-23 | Immatics Biotechnologies Gmbh | Bispecific molecule formulation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007032255A1 (ja) | 2005-09-13 | 2007-03-22 | Mie University | Ｔ細胞レセプター及び該レセプターをコードする核酸 |
| WO2008053579A1 (en) | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Antigenic polypeptide usable as therapeutic agent for malignant neoplasm |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011304728A1 (en) | 2010-09-20 | 2013-03-14 | Biontech Ag | Antigen-specific T cell receptors and T cell epitopes |
| AU2012236068A1 (en) * | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
| US20140322344A1 (en) * | 2011-08-31 | 2014-10-30 | National University Corporation Tokyo Medical And Dental University | Vaccine preparation for cancer treatment |
| WO2013057596A1 (en) | 2011-10-21 | 2013-04-25 | Atena Srl | Anatomic cushion accumulator for thermal treatment with heat or cold |
| GB2508414A (en) * | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| JP6164759B2 (ja) | 2013-11-21 | 2017-07-19 | Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 | Ｔ細胞受容体およびｂ細胞受容体レパトアの解析システムならびにその治療および診断への利用 |
| US10202640B2 (en) * | 2014-05-07 | 2019-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing |
-
2016
- 2016-03-16 GB GBGB1604492.7A patent/GB201604492D0/en not_active Ceased
-
2017
- 2017-03-16 MA MA043720A patent/MA43720A/fr unknown
- 2017-03-16 SG SG11201807868VA patent/SG11201807868VA/en unknown
- 2017-03-16 US US15/460,654 patent/US10538573B2/en active Active
- 2017-03-16 WO PCT/EP2017/056260 patent/WO2017158103A1/en not_active Ceased
- 2017-03-16 CN CN201780017511.6A patent/CN108884136B/zh not_active Expired - Fee Related
- 2017-03-16 KR KR1020217015786A patent/KR102457504B1/ko active Active
- 2017-03-16 MY MYPI2018703216A patent/MY189042A/en unknown
- 2017-03-16 MA MA43330A patent/MA43330B1/fr unknown
- 2017-03-16 TW TW106108700A patent/TWI764886B/zh not_active IP Right Cessation
- 2017-03-16 CA CA3017502A patent/CA3017502A1/en active Pending
- 2017-03-16 JP JP2018548022A patent/JP7340127B2/ja active Active
- 2017-03-16 EP EP17710955.0A patent/EP3430030B1/en active Active
- 2017-03-16 AU AU2017235467A patent/AU2017235467B2/en not_active Ceased
- 2017-03-16 MX MX2018011225A patent/MX2018011225A/es unknown
- 2017-03-16 CR CR20180492A patent/CR20180492A/es unknown
- 2017-03-16 KR KR1020187029016A patent/KR102259109B1/ko not_active Expired - Fee Related
- 2017-03-16 EA EA201892021A patent/EA201892021A1/ru unknown
-
2021
- 2021-07-07 AU AU2021204753A patent/AU2021204753A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007032255A1 (ja) | 2005-09-13 | 2007-03-22 | Mie University | Ｔ細胞レセプター及び該レセプターをコードする核酸 |
| JP2013126415A (ja) | 2005-09-13 | 2013-06-27 | Mie Univ | Ｔ細胞レセプター及び該レセプターをコードする核酸 |
| WO2008053579A1 (en) | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Antigenic polypeptide usable as therapeutic agent for malignant neoplasm |
Non-Patent Citations (1)
| Title |
|---|
| British journal of cancer，2009年，Vol.100, p.1135-1143 |
Also Published As
| Publication number | Publication date |
|---|---|
| EA201892021A1 (ru) | 2019-02-28 |
| US10538573B2 (en) | 2020-01-21 |
| TWI764886B (zh) | 2022-05-21 |
| CA3017502A1 (en) | 2017-09-21 |
| JP2019511222A (ja) | 2019-04-25 |
| KR20180118783A (ko) | 2018-10-31 |
| MA43330B1 (fr) | 2020-06-30 |
| MA43720A (fr) | 2018-11-28 |
| EP3430030B1 (en) | 2023-12-20 |
| CN108884136B (zh) | 2023-03-17 |
| CR20180492A (es) | 2019-01-31 |
| WO2017158103A1 (en) | 2017-09-21 |
| AU2017235467A1 (en) | 2018-11-01 |
| US20170267738A1 (en) | 2017-09-21 |
| KR102259109B1 (ko) | 2021-06-01 |
| GB201604492D0 (en) | 2016-04-27 |
| AU2021204753A1 (en) | 2021-08-05 |
| TW201736396A (zh) | 2017-10-16 |
| SG11201807868VA (en) | 2018-10-30 |
| KR102457504B1 (ko) | 2022-10-20 |
| EP3430030A1 (en) | 2019-01-23 |
| KR20210063486A (ko) | 2021-06-01 |
| MY189042A (en) | 2022-01-21 |
| MX2018011225A (es) | 2018-11-22 |
| MA43330A1 (fr) | 2019-07-31 |
| AU2017235467B2 (en) | 2021-04-08 |
| CN108884136A (zh) | 2018-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7559120B2 (ja) | がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体 | |
| CN108884136B (zh) | 用于癌症免疫治疗的转染t细胞和t细胞受体 | |
| AU2017235069B2 (en) | Transfected T-cells and T-cell receptors for use in immunotherapy against cancers | |
| US11730796B2 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| HK40099489A (zh) | 用於癌症免疫治疗的转染t细胞和t细胞受体 | |
| EA043021B1 (ru) | Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний | |
| BR122024024508A2 (pt) | Construto reconhecedor de antígeno, ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método de fabricação de uma linhagem celular que expressa um construto reconhecedor de antígeno aat específico | |
| NZ747154B2 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| HK40003640A (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| HK40003640B (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200305 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200305 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210426 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210726 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210721 Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210726 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210902 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220113 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220407 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220712 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220809 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221107 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230213 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20230227 |
|
| RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20230302 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230303 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230316 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230314 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7340127 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |